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Abstract 
The use of cognitive enhancement drugs (CEDs) among university students has raised widespread 
concerns about non-medical prescription drug use, safety, exam cheating, and study-related stress. 
While much of the empirical research to date has been conducted in the United States and Australia, 
this article examines perceptions and experiences of CED use among university students in the 
Netherlands and Lithuania. Our data comes from two qualitative studies and one mixed-methods 
study drawing in total of 35 semi-structured interviews (20 in the Netherlands; 15 in Lithuania) and 
from open-ended online survey responses among a convenience sample of 113 students in the 
Netherlands. Employing a crowded theory approach to interpret our qualitative data, we found most 
of our informants turned to CEDs to enhance their studying through better concentration and time 
management. Students used a broad range of pharmaceuticals (with and without a physician’s 
prescription), recreational drugs, and nutritional supplements as cognitive enhancers, were generally 
well informed about the safety and efficacy of the substances they used, experienced both beneficial 
and adverse effects, and self-regulated their CED use to balance these effects, ensuring that their 
use remained moderate and thoughtful.  
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Introduction 
The use of psychoactive substances by university students seeking to improve academic 
performance has attracted the attention of researchers, bioethicists, and government officials. While 
earlier research centered on North America and Australia, recent years have witnessed increased 
interest in many European countries, including the United Kingdom, Germany, and Switzerland 
(www.nerri.eu/; Maier et al., 2013, 2015a, 2015b; Singh et al., 2014; Forlini et al., 2015; for 
reviews see Ragan et al., 2013; Maier & Schaub, 2015). Pharmacological neuroenhancement or 
“the misuse of prescription drugs, other illicit drugs, or alcohol for the purpose of enhancing 
cognition, mood, or prosocial behavior in academic or work-related contexts” (Maier & Schaub, 
2015, p. 156) has been the subject of numerous government reports and policy guidelines from 
medical associations (for a review, see Outram & Racine, 2011). The phenomenon has also 
attracted media attention, which often exaggerates the popularity and efficacy of “smart drugs” 
(Partridge et al., 2011; cf. Williams et al., 2008; Forlini & Racine, 2009). Although estimates of 
prevalence vary widely, studies suggest that cognitive enhancement drugs (hereafter CEDs)—
including methylphenidate (e.g., Ritalin™) and dextro-amphetamine (e.g., Adderall™), used 
mainly to treat Attention Deficit/Hyperactive Disorder (ADHD), and modafinil (Provigil™), a 
wakefulness-promoting drug used mainly to treat narcolepsy—are being used by many individuals 
without diagnosed medical conditions (Coveney et al., 2011).  
 
Singh and Keller (2010, p. 5) suggest that “the use of stimulants as neuroenhancers appears to be a 
growing trend among university students around the world.” Neuroenhancement, however, admits 
to different interpretations (e.g., Arria & Wish, 2006), requiring caution when interpreting figures 
on prevalence. Most commonly cited surveys also differ in their methods, sampling, sample size, 
and questions, requiring caution when examining epidemiological patterns of CED use. It is also 
difficult to transfer findings from the USA to Europe due to different regulatory and educational 
contexts. In general, European studies have shown lower prevalence rates than American ones (e.g. 
Mache et al., 2012; Ragan et al., 2013; Maier et al., 2013; Schelle et al., 2015). Nevertheless, 
students in at least some European countries seem well aware of the phenomenon, including 93.7% 
of respondents of a survey of 6,275 Swiss students (Maier et al., 2013; cf. Forlini et al., 2015).  
 
While clinical trials have found the efficacy of CEDs among individuals without medical conditions 
to be either non-existent or limited (e.g., Repantis et al., 2010; Ilieva et al., 2015), this does not 
match reported user experiences in non-clinical settings (Ilieva et al., 2013). This could be due to 
the placebo effect or the inadequacy of experimental trials to simulate real-life environments 
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(Ragan et al., 2013). Lack of agreement on standardized tests problematizes measuring effects 
among healthy volunteers (Husain & Mehta, 2011). Although surveys, clinical experiments, and 
commentaries by bioethicists have addressed the use of CEDs by healthy individuals, “there is at 
present a lack of findings from in-depth, qualitative research that examines the everyday uses and 
users of medications” (Vrecko, 2013, p. 5). As Smith and Farah (2011) argue, we need to better 
understand how CEDs work in everyday practice as opposed to laboratory settings. 
 
Despite the limited clinical evidence on efficacy for healthy individuals, the phenomenon of 
pharmacological neuroenhancement has produced numerous academic commentaries concerning its 
ethical, social, and policy implications for non-clinical populations (e.g., Farah et al., 2004; 
Bostrom & Sandberg, 2009; Sahakian & Morein-Zamir, 2011; Hyman, 2011). Critics have 
cautioned bioethicists for making unsubstantiated claims about the effects and prevalence of CED 
use, pointing out that the off-label use of psychoactive substances for enhancement purposes is 
hardly new (e.g. Schermer et al., 2009; Gilbert & Baertschi, 2011; Bell et al., 2012; Illieva & Farah, 
2013). Others have warned that the growing research and media interest could inflate “a 
neuroenhancement bubble” (Lucke et al., 2011). Students often perceive substance use among peers 
as more common than it really is, and the more aware students become of others using CEDs, the 
more they may be inclined to see it as the norm (e.g. Perkins, 2002; McCabe, 2008; Outram, 2010). 
The challenge for policy-makers, educators, and harm-reduction practice, then, is to provide 
credible information on the possible harms and effects of CEDs without accelerating their use (cf. 
Schelle et al., 2014, 2015). 
 
Extant studies report similar motivations for university students to use CEDs. Prescription 
stimulants are most often used during periods of high academic stress (DeSantis et al., 2008, p. 319; 
cf. Hildt et al., 2014). Methylphenidate is also used for recreational purposes (DuPont et al., 2008). 
Aikins’ study of licit and illicit users of prescription stimulants on an American university campus 
found that both types of users “overwhelmingly felt that prescription stimulants enhanced their 
ability to perform academic tasks” (2011, p. 566; cf. Vrecko, 2013). They also reported unpleasant 
side-effects which were deemed to be “worth it.” In addition to improving academic and cognitive 
performance, Mache et al. (2012) found German students using CEDs to cope with stress and 
pressure to succeed, out of curiosity, because others were doing it, and because they feared being at 
a disadvantage to CED-using peers. Because they are commonly used, legal, and seen to have fewer 
side-effects or addiction potential than “hard drugs,” young people are often not afraid to 
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experiment with prescription medications, which they view as “soft drugs” (Quintero, 2012, p. 513–
9; cf. Green & Moore, 2009; DeSantis & Hane, 2010). 
 
This article seeks to add to our knowledge on the practice of cognitive enhancement in real life 
settings by exploring perceptions and experiences among university students in the Netherlands and 
Lithuania. We explore reasons why students turn to neuroenhancement, what effects—both desired 
and adverse—they experience, how they obtain information about CEDs, and control their use to 
maximize benefits and minimize harms. Based on our findings, we argue that the use of CEDs by 
healthy individuals is best understood as functional drug use (cf. Boys et al., 1999; Boys, Marsden 
& Strang, 2001). Most students had clear goals behind their CED use, were well informed about the 
safety and efficacy of the substances they used, experienced both beneficial and adverse effects, and 
self-regulated their use to balance benefits and harms. 
 
Methods 
Our data are drawn from three studies based on semi-structured interviews with current or recently 
graduated university students (20 interviews in the Netherlands and 15 interviews in Lithuania). 
One of the studies also included an online survey (N=113) among students in the Netherlands, 24 of 
whom reported having used CEDs in study situations. The original datasets were gathered 
separately without a collaborative study design. The researchers met in early 2015 in a workshop 
organized by the Chemical Youth project to discuss common themes emerging from our separate 
datasets.  
 
Study participants included both students with and without a neuropsychiatric diagnosis as we 
found their experiences to be broadly similar. Although the extant literature generally draws a sharp 
distinction between the use of CEDs for therapeutic reasons and for enhancement—i.e., with and 
without a physician’s diagnosis—we found this neat distinction broke down in practice. Some of 
our informants who had been diagnosed with AD(H)D used medications without prescriptions; 
others, without having been diagnosed by medical professionals, were convinced that they suffered 
from attention disorders or daytime sleepiness. Other studies have revealed that students fake 
symptoms to obtain prescriptions for enhancement purposes (e.g., Petersen et al., 2014), further 
blurring the distinction between the therapeutic use of medicines and their off-label use for 
enhancement.  
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All informants gave their oral informed consent to participate in the study and were guaranteed 
anonymity. All names in this article are pseudonyms.1  
 
Interviews 
The semi-structured interviews, which took place between March and December 2013, were 
recorded and transcribed verbatim in English or in their original Dutch and Lithuanian; excerpts 
here have been translated and edited for clarity. Informants were recruited mainly by snowball 
sampling from personal networks in the Netherlands, and additionally by adverts in students’ 
mailing lists, personal Facebook pages, and through a small youth community website in Lithuania. 
The sole inclusion criterion was that the informant had used a substance to enhance their work or 
studying (in Lithuania) or had experience using a cognitive enhancement drug (in the Netherlands). 
Some interviewees used psychostimulants with a doctor’s prescription; others used them off-label. 
Some, mostly in Lithuania, used “recreational” drugs as well as vitamins and nutritional 
supplements marketed as supporting mental work as CEDs.  
 
Twenty interviews took place in Amsterdam; 15 in Vilnius and Kaunas, Lithuania. The 
interviewees—15 males and 20 females—ranged in age from 19 to 29, with a mean age of 23. Eight 
interviewees had been diagnosed with ADHD/ADD, and one with daytime sleepiness; three were in 
the process of getting a medical diagnosis or had diagnosed themselves as having ADD or daytime 
sleepiness. Ritalin and Concerta were the most commonly used CEDs, while Modafinil, Racetam-
group substances, Ephedra, Gingko Biloba, food supplements for the brain (e.g. Neurozan), 
vitamins, cannabis, amphetamine, methamphetamine, GABA, cocaine, and LSD were also 
mentioned by interviewees as cognitive enhancers.  
 
Survey 
An online survey was distributed through Facebook and via email through academic managers (for 
a review of using Facebook in the social sciences, see Wilson et al., 2012). The survey consisted of 
24 questions, developed by the first author after an initial round of six interviews. Data obtained 
from these initial interviews informed the design of the questionnaire, which included questions on 
basic demographics, substances used, reasons for use, and perceived effects. The survey was posted 
                                                          
1 The data presented in the article were collected during research conducted for Medical Anthropology and Sociology 
MA thesis projects (in the case of Hupli and Didžiokaitė) and an Anthropology BA thesis (Ydema) at the University of 
Amsterdam, following standard ethics operating procedures which include use of pseudonyms and informed consent. 
The analysis presented was conducted with support of the ChemicalYouth project which is led by Anita Hardon. The 
ChemicalYouth project has been approved by the ethics committee of the University of Amsterdam Faculty for Social 
and Behavorial studies. 
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as a direct web link on social media student groups affiliated to the University of Amsterdam and 
the VU University Amsterdam, and was open from the beginning of April 2013 to the end of May 
2013. These groups had in total almost 3,000 members at the time. The convenience sample 
consists of 113 respondents of whom 71% were female, and 78% between the ages of 18 and 24. 
Half were social sciences and humanities majors; medical students, at 35%, were the second largest 
group. 59% of the respondents were Dutch, 25% were from another European Union country, and 
15% from a non-EU country (one respondent had an unclear country of origin).  
 
Of the 113 respondents, 24 (21%) reported having tried CEDs, defined in the survey as 
“prescription medication (for example Ritalin, Concerta, Modafinil, Adderall) used to affect study 
situations.” Ten of these 24 students had been diagnosed with a medical condition (mostly 
ADD/ADHD, N=8). The lifetime prevalence of off-label CED use was therefore 12% (N=14). Most 
had discontinued use suggesting that the point prevalence rate of off-label CED use was 1.8% 
(N=2), which is in line with other European surveys showing relatively low prevalence rates of off-
label CED use compared to the US (Mache et al., 2012; Ragan et al., 2013; Maier et al., 2013; 
Schelle et al., 2015). Half of the respondents (N=12) who had tried CEDs reported using them less 
than once per semester; five reported using once per semester. Four respondents reported daily use 
and all were diagnosed with ADD/ADHD. This indicates that CED use was also infrequent. Several 
medications for ADHD were the most commonly mentioned in the survey responses: Ritalin 
(N=19), Concerta (N=6), and Adderall (N=4). Other substances used for enhancement purposes 
included Modafinil (N=1), Racetam-group substances (N=2), and benzodiazepines (Oxazepam, 
Lorazepam, and Diazepam) (N=2). Almost half (N=11) of the survey respondents who reported 
having tried CEDs named more than one substance. 
 
The survey respondents are not a representative sample of the student population in Amsterdam but 
the survey data served to triangulate our interview findings. Conversely, the interview data helped 
to elaborate upon findings from the survey. 
 
Analysis 
The qualitative data sets that make up this article embraced a grounded theory approach (Glaser & 
Strauss, 1967) that builds theory from collected data, privileging user experiences without imposing 
a preordained framework on their accounts. In analyzing our collective data, we made use of Bröer 
et al.’s (forthcoming) crowded theory approach, in which “the idea is to use the power of online 
tools to enhance collaboration, validate interpretations and co-author conclusions in qualitative 
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research” (http://aissr.uva.nl/news/content/2014/09/crowded-theory.html). Crowded theory relies on 
the collective interpretation of data sets rather than line-by-line coding by individual researchers. 
Although designed for larger groups of analysts, it suited our purposes as we were not aiming to 
develop new theoretical categories, but to explore emerging themes which arose from comparative 
interpretations of our data. As none of us were trained in using Bröer et al.’s novel software, we 
relied on Google Docs, video calls on Skype, and email exchange when comparing interpretations 
of our data. 
 
In the first phase of analysis we shared with each other the relevant excerpts from our original 
interviews and the open-ended qualitative responses from the survey. This allowed us to compare 
initial interpretations of our own data with that of the other two researchers. In the second phase we 
analyzed these thematic datasets, first individually and then as a group. Although the aim of 
collaborative interpretation is not to continue until consensus is reached but to give participating 
researchers the possibility to agree to disagree (Bröer et al., forthcoming), there were no major 
disagreements over our interpretations, adding to the validity of our findings.  
 
Why use cognitive enhancement drugs? 
University students in the Netherlands and Lithuania reported many different reasons for using 
CEDs. Of the 24 Amsterdam survey respondents who had taken CEDs, five had doctors’ 
prescriptions. Twelve others, without prescriptions, had tried CEDs to enhance their studying, while 
six reported using CEDs recreationally or out of curiosity. Interviewees mentioned getting better 
grades, being more creative, staying awake in class after a night out, better managing time, and 
improving performance while working, travelling, or doing sports as reasons to use CEDs. The 
breadth of reported reasons to use CEDs echoes the findings of Partridge et al. (2013), who found 
students using prescription stimulants for all sorts of lifestyle reasons and not solely to enhance 
cognition in academic contexts (cf. DeSantis et al., 2008; Hildt et al., 2014).  
 
Brian explained the range of purposes for which he and his friends used off-label Modafinil: 
 
We used it for working and for partying. So you go to a club until late and then you drive home 
sometimes. We took it to be awake in the car so you don't have car accidents. And we took it while 
raving to be like sharp and the next day you could still work. And we took it while studying. 
Enhancement actually for tests and stuff. 
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Echoing previous studies (DeSantis et al., 2008; Hildt et al., 2014), our informants who used CEDs 
to enhance academic performance were broadly seeking two goals: improved concentration and 
more effective time management. The latter often meant more studying in less time or extending the 
time of studying. Frank used CEDs off-label before he was diagnosed with ADD: 
 
Yeah, with most of my friends, I spoke to a couple of them because I knew I was going to be 
interviewed, most of them told me that they do as I do myself: when their deadline comes closer and 
you're running out of time, you use it mainly to stretch the limited time you have to its maximum 
potential so you can work in the night and still function in the day or the other way around. You can 
work in the daytime and then you use your nighttime to do your job or to have your social life. But 
you're reducing, severely reducing your amount of sleep. And then I think the second reason for most 
people is concentration.  
 
Experimenting with CEDs was also occasionally linked to the knowledge students had acquired 
from their studies. Gabriel had tried Modafinil and Racetam-type drugs mainly to get better grades 
and improve memory, but also because it’s “related to psychology and you do a lot of stuff about 
memory and a lot of stuff about neurotransmitters and stuff, so I think I was quite interested if I 
could sort of change it all.” 
 
Students often expected CEDs to work as smart drugs, with their expectations following the drug’s 
pharmacological profile in therapeutic settings. Ritalin was expected to improve concentration and 
wakefulness, Racetam-group substances to improve memory, and Modafinil to help stay awake and 
study longer: 
 
Aleksi Hupli [AH]: Before you used them, what did you expect to happen? 
Gabriel: I don’t really know. I think I expected to be able to remember things better with the 
Racetam type of drugs. I think I just expected to remember better. With Modafinil I expected to be 
able to sit there for longer and study for longer. I don’t think I had any strong expectations but you 
know those are the two things they say, well people have said they do so.  
 
Experienced effects 
Did students using CEDs achieve their desired aims? With Ritalin, many of our undiagnosed 
informants expected improved concentration and wakefulness. But they were often disappointed 
with the results, either not feeling the effects at all or finding them to be mild and only slightly 
beneficial: 
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AH: Did it [Ritalin] work?  
Fiona: Umm, well I passed the exam but didn’t really have the feeling that the drug did anything. 
 
Bella: Yeah well, a little. Like usually I just go on Facebook all the time if I’m studying, I’m really 
unfocused and all over the place but when I took it, Facebook wasn’t interesting anymore for a 
while, but I didn’t feel super-smart or super-focused or anything. 
 
Taking Ritalin was no panacea; one still had to study. It could reduce distractions but did not make 
one, as was often expected, “super-focused.” Uncertainty about effectiveness—whether it was 
prescription medication or a food supplement—was common. Students were cautious in judging 
efficacy and acknowledged that the changes they experienced might be a subjective effect or a 
placebo: 
 
Vaiva: I hoped that [vitamins for memory] will help, maybe because I had such hopes, I started at 
some unconscious level to be more attentive, but you can’t dig into it now. Maybe it worked as a 
placebo effect as well, now I no longer know. 
 
Henry: Yeah it’s also the, what's it called... the effect from a pill that... 
AH: The placebo? 
Henry: Yeah, the placebo effect. That's also why I sometimes just take a quarter or a crumble of it 
just because I know I will think that it does work but it’s not even because of the pill. It´s just my 
head that thinks it works. But that´s enough sometimes (laughter). 
 
Despite often being disappointed with the actual effects—and sometimes acknowledging that the 
positive effects were due to their expectations—some students did report increased focus, 
motivation, and creativity, which encouraged them to continue using CEDs. Vrecko (2013) has 
pointed to the role played by emotions in students’ use of CEDs to improve academic performance. 
Diane indeed confirmed that the effects of taking Ritalin were largely motivational:  
 
First I tried like half a pill and the second time I took a whole pill. So that’s about it… I felt like now 
that I took a pill I should study. It was more like a motivation for myself than it was an actual 
physical effect. So it was more like oh my god I’m going to take a pill so I better study [laughter]. I 
think I was a bit distracted and figured that, well, at the point that I’m taking this pill to study, 
everything seems to open to study. 
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Mo (self-diagnosed with ADD) emphasized that Ritalin “does not work if you don’t give a shit. 
You can take two Ritalins, but then it won’t work anyway. You have to be like: well, ok, I want to 
learn now.” Having the motivation to study seemed to be a prerequisite for CEDs to have their 
desired effects. Other studies, however, have pointed to students experiencing positive effects from 
CEDs even when their quest to obtain better grades remained unfulfilled (Partridge et al., 2013; 
Hildt et al., 2014).  
 
Greater focus, motivation, and creativity 
Eighteen of the 24 survey respondents who had used CEDs reported improved concentration; a 
further four reported increased attentiveness and improved memory. Many of our interviewees also 
reported that CEDs enabled them to better concentrate and remain focused. Henry (undiagnosed) 
had used Ritalin and Concerta about 50 times in the past nine years:  
 
AH: Could you describe the effects that you feel when you study with [Ritalin]? 
Henry: Yeah, the most important thing is that my concentration goes up a lot so I can study for three 
hours in a row... and doing just one thing instead of just studying for one hour and doing other 
things at the same time and actually not really studying. That’s the main thing. And the studying 
days are a lot longer. 
 
Although Roderick was undiagnosed at the time of the interview, he was convinced that he had 
ADD and received Ritalin from his diagnosed sibling: 
 
Roderick: Then I did [take Ritalin for the first time] and I suddenly had an enormous focus. I found 
it quite heavy. Normally there are a thousand things haunting through my head, but after using 
Ritalin I really had only one goal, and that was studying, studying, studying. 
MY: How does it feel? 
Roderick: What I said. Instead of getting constant stimuli from outside, or also just in your head, 
that is sort of cancelled out. You can think about other things than the things you have to learn, but 
the moment you want to think about one thing you only think about that thing and you don’t get 
distracted by something from outside or from your own head. You are just totally concentrated. 
 
Most of our informants had tried a variety of recreational drugs. Frank, who had used amphetamine 
and Ritalin to improve his focus before being diagnosed with ADD, stated that taking LSD had also 
improved his creative thinking: 
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I got stuck in that specific paper for a week without you know anything on your screen and then in 
the final 36 hours I told my girlfriend, ok this is all shit. After I took the LSD I deleted I think 80% 
and rewrote the whole thing in I think 24 hours and then I handed it in and got an 8.5. That was 
good. I do consider that cognitive enhancing but in a completely different way. So the classical thing 
would be amphetamine.  
 
When asked whether he had used CEDs just to get high, Brian responded: 
 
No, no. But it is a good feeling when you wake up, you take your pill, you drink a coffee. And you’re 
sometimes a little bit high in the morning. It feels like ecstasy, like when ecstasy hits. It is a good 
feeling. I did a little methamphetamine with my Bachelor’s thesis. It’s great because you’re so into 
it. But then I discovered Oxazepam too, to get all the thoughts away. I don’t know. I also think that’s 
the thing that’s coming up. Because people know that you can combine it, it’s even better and it’s 
like yeah… and Oxazepam is also everywhere, it’s very cheap. 
 
The passages above suggest that the experienced effects of CEDs are comparable to those of 
recreational drugs; that they affect not only cognition but also mood and creativity; that illicit drugs 
are also used as study aids; and that prescription drugs such as Oxazepam and psychedelics which 
are rarely considered as cognitive enhancers are also used for this purpose. As our aim was to let 
users define what they perceived as CEDs, this raises issues for future studies. Our data also reveals 
the difficulty of clearly distinguishing between the use of CEDs for therapeutic and enhancement 
purposes. Some students without an official diagnosis were convinced they had ADD; others who 
had been diagnosed refused to accept the disease label. Some diagnosed students still obtained the 
drugs illegally or did not follow the treatment regimes prescribed by their doctors. Nevertheless, 
when describing the effects of stimulants, our informants had typically similar experiences. 
 
Side-effects  
What side-effects did students experience from their use of CEDs? Both diagnosed and 
undiagnosed students reported adverse side-effects, especially when using prescription drugs. 
Eighteen of the 24 survey respondents who had used CEDs reported a variety of side-effects 
including loss of appetite, sleeplessness, nervousness, and increased agitation. These findings from 
the survey were largely corroborated in the interviews.  
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Lotte (diagnosed with ADD) experienced numerous side-effects: she lost a lot of weight and had 
almost black and blue hands and feet, a condition called Raynaud’s disease. She only used Ritalin 
when she felt she really needed to: “I only take Ritalin if I am chaotic in my head for a really long 
period of time, and if I see no other option.” Amelia (diagnosed with ADD at age 12, later with 
ADHD) felt that ADHD medication worked for her, even though she experienced side-effects like 
depression and appetite loss. But she reported adverse effects when the medications wore off. 
Cecilia (diagnosed with ADD) decided to stop using Ritalin for “as soon as the effect wore off, my 
muscles were very sore and tense and it felt like my body had cramped up for a couple of hours.” 
 
Undiagnosed students also suffered adverse effects. Some, like Anna who used Ritalin once before 
her final exams, “got really anxious and nervous and uptight and a little paranoid and just uneasy.” 
Eglė (self-diagnosed with daytime sleepiness) found that Modafinil “slightly erases my memory. It 
feels like I’m doing tasks, but the next day I might not remember what I was doing.” When asked 
whether taking CEDs helped his studies, Gabriel answered that his grades actually went down 
because he was distracted by worries that “I was going to die, you know, because there’s lots of 
stuff about Modafinil and getting like all sorts of crazy skin diseases.” 
 
Despite experiencing benefits, Jasper (diagnosed with ADD) eventually decided to quit taking 
Ritalin due to its side-effects (for him, aggression, difficulty sleeping, and feeling down). He 
struggled to balance Ritalin’s benefits and harms: 
 
Marte Ydema [MY]: How do you feel when you use Ritalin? 
Jasper: It is just emptying your head and you can totally commit to something. Look, Ritalin has a 
lot of advantages, but now it is the question if it is worth the disadvantages. 
 
Self-regulation 
Almost all of our informants experienced both beneficial and adverse effects and tried to balance 
between them. Before consuming CEDs, many of our study participants tried to inform themselves 
about the substance they intended to use. Some simply read the drug’s patient information leaflet. In 
other cases, the drug was given to them or recommended by trusted friends or relatives: 
 
AH: Did you look up information about it [Modafinil] before you used it? 
Emilia: No, just from my friends who told me it was this drug that the army used and it was to stay 
awake and stay focused. 
13 
 
AH: So you got that information from your friend? 
Emilia: Yeah, my friends because they were using it more often.  
 
Others researched the substance online, gathering information about its effects, possible risks, and 
usefulness: 
 
AH: Did you look at information about them before using? 
Gabriel (undiagnosed): Yeah, definitely, Wikipedia was a good source but there was also a forum 
called LongeCity, I think it was called, and it’s just a forum which is not primarily for talking about 
cognitive enhancements and nootropics or anything but… that’s been like one of the main focuses on 
people talking about it and talking about new drugs. 
 
Others combined information from friends and the internet. Kipras (undiagnosed) was 
recommended Armodafinil by his ex-girlfriend and wanted to be better informed: 
 
Gabija Didžiokaitė [GD]: Why did you look for info online? What did you want to find out? 
Kipras: Well, just when you’re doing something unfamiliar you want, well, to know more. 
GD: Because it’s a drug, or just because? 
Kipras: I’m just watching out. If I would hear that there’s a big risk, that something bad will happen 
or something, then I wouldn’t have agreed [to use it]. 
GD: So in a sense you were trying to get more info about that [Armodafinil], to find out more about 
side-effects? 
Kipras: Not necessarily side-effects, just effect. If it’s worth it in general. 
 
Students who had been diagnosed with a medical condition would, in addition to other sources, turn 
to their doctor for information. But being diagnosed by a medical professional did not necessarily 
translate into faith in the treatment: 
  
AH: When you got the diagnosis and got prescribed did you look up, well you probably got 
information from your doctor but did you look up information yourself as well? 
Cecilia (diagnosed with ADD): I did, I googled it of course and I got some information from my 
doctor, but looking back… I think I did not do enough research because I could have known that 
Ritalin is only helpful if you're really active, if you really have ADHD and I knew I didn't have that. 
So it was kind of strange why he prescribed that to me but you know then again I´m kind of 
experimental. 
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Being informed boiled down to two themes: safety and efficacy. One needs to “watch out” and be 
aware of a drug’s side-effects and other risks. Students sought information on usual dosages and 
how these can be adjusted depending on their needs, to avoid both over and under dosage and to 
foster safe and efficient use. Students using illegal substances also emphasized the importance of 
knowing where and whom the drugs came from to avoid fake or dangerous products. By searching 
for information on the effectiveness of a substance and other people’s experiences with it, they 
knew what (not) to expect and whether it fit their needs. 
 
Students who spent more time researching CEDs had specific ideas about what information was 
relevant as well as which sources were reliable. Our findings here echo those of Quintero and 
Bundy (2011): that most young people know how to navigate the wealth of information online and 
determine which sources are reliable. Some study participants only trusted scientific research.  
 
GD: So you know [the effects and side-effects] of all of the substances you use? 
Petras: Yes, I know it all. 
GD: Side-effects? 
Petras: Side-effects and so on. For example Creatine, they say that it ruins your kidneys, it shouldn’t 
be used. Scientist checked: they gave it to an ill person with only one kidney. Nothing, 20 grams per 
day, for a month—nothing, normal. 
GD: But if there’s a risk, aren’t you afraid to use it? 
Petras: I’m not afraid. Until there’s a scientific basis that it is [dangerous]. 
 
University students using CEDs in both the Netherlands and Lithuania emphasized the importance 
of being well informed. In this, they differed from their often-studied American peers (DeSantis et 
al., 2009; DeSantis & Hane, 2010; Aikins, 2011). The widespread concern to learn as much as 
possible about the CED and its possible dangers—whether the drug was prescribed, used off-label, 
or illicit—translated into a greater sense of control over the experience. 
 
DeSantis and Hane (2010) found that many of their American student informants regulated their 
CED use by limiting it to important assignments and exams, looking askance at peers who did not 
regulate their use. Many of our informants in the Netherlands and Lithuania expressed similar ideas: 
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Maria: I don’t know, I have nothing against [cannabis], but on the other hand, there is this, I don’t 
know maybe it’s mom’s influence, that even if it’s nothing bad, but still, it shouldn’t be done often. 
This kind of thinking. Because if it would be super good, I could use it every day. But why am I not 
doing that? Probably because I think it shouldn’t be done every day. 
 
Jovita: I would only use [food supplement] on certain days, not before all the tests, when it seems 
easy, then it doesn’t matter, but if there’s an exam, my hands and legs are shaking, then I would take 
it. 
 
Numerous students expressed variations of the idea that there can be too much of a good thing. 
Using any substance too frequently undermines its purposive use; when this happened, CEDs were 
no longer valued positively. Some stated that CEDs should only be used reasonably, and that users 
needed to be clear about their motives: 
 
Steponas: I think, that [smoking cannabis] needs... to be done, as long as you know, why you are 
doing it. As long as you know, that it has an aim, as long as you can control it in some way. 
 
Viktorija: Yes, I think it’s safe and healthy, if you’re doing it mindfully and with help, if you need 
[lithium], if it suits you, then why not.  
 
The great majority of our informants perceived their use of CEDs to be serving a clear purpose, and 
sought to limit their use to aiding the performance of specific tasks.  
 
Discussion 
In this article we sought to contribute to the current academic, policy, and media discussion on 
neuroenhancement by focusing on the perceptions and experiences of university students in the 
Netherlands and Lithuania. Although the generalizability of our findings to student populations in 
these countries is limited, they do give a more nuanced picture of the use of CEDs in everyday life.  
 
Our student informants used a plethora of substances for cognitive enhancement, broadly construed. 
Although prescription stimulants prevailed in our Dutch data sets, they were far from the only 
substances used by students, while in Lithuania more students turned to nutritional supplements and 
illicit drugs. While these differences could in part be due to the recruitment strategies of the studies 
that inform this article, they also reflect the availability of psychostimulants in the two countries, 
rooted in psychiatric practice. According to the International Narcotics Board (2014), the 
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Netherlands is the eleventh largest consumer of Schedule II stimulants in the world; routine 
prescription by psychiatrists leads to much higher diversion potential for enhancement purposes. In 
contrast, psychostimulants are rarely used to treat adult ADHD in Lithuania, while pharmacological 
treatments have only recently been introduced for children (Lithuanian Society of Child and 
Adolescent Psychiatry, 2015).  
 
Future research needs to take into account the great variety of substances that students perceive and 
use as CEDs in real life settings. The breadth of substances that our informants used as 
neuroenhancers echoes the findings of a recent survey which asked university students in the UK 
and Ireland to define smart drugs. While most students pointed to stimulants (caffeine pills, 
methylphenidate, energy drinks, Modafinil, Adderall, speed), others also identified vitamin 
supplements, cannabis, LSD, and tranquilizers as smart drugs (Singh et al., 2014). 
 
The range of substances used by students for cognitive enhancement furthermore suggests that they 
are pursuing different effects: enhanced focus, motivation, memory, or creativity; better nighttime 
sleep or less daytime sleepiness; stimulation or relaxation. We found our informants to consider 
different mental and physical states as beneficial. But although the desired effects differed, how 
prescription stimulants, illicit drugs, supplements, and vitamins were perceived and employed as 
functional “tools” to attain specific goals was broadly similar.  
 
While some of the effects experienced by our informants were clearly functional, others were 
adverse (cf. Van den Ende et al., 2010). Both students with and without diagnosed medical 
conditions had to balance the beneficial and adverse effects they experienced from their use of 
CEDs. Some students were puzzled by the efficacy of the CEDs they consumed and attributed 
positive effects to a possible placebo effect (cf. Moerman, 2002). The concept, first applied in the 
context of medicines and treatment, can readily be applied to practices of enhancement outside of 
medical supervision.  
 
For our student informants, the use of CEDs was not—as critics often assume—a reckless 
undertaking driven by peer pressure. They self-regulated their use of CEDs, wanting it to be 
moderate, controlled, and occasional. They found it important to be conscious of the reasons why 
they took CEDs; when they were mindful of their use, they felt more responsible and in control of 
the substance, rather than being controlled by it. Losing control over one’s use was associated with 
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addiction; knowing why one uses CEDs and using them rationally were thought to inhibit addiction 
and dependence.  
 
Students reported two main reasons for being well informed: to be safer in their use and to make the 
most of the CED. By being informed about the drug’s efficacy and other people’s experiences with 
it, they learnt what to expect and how to interpret its effects (cf. Becker, 1963). Even those who 
used vitamins or food supplements—generally considered as “soft enhancement” (Maier & Schaub, 
2015)—sought to be well informed. Most students used CEDs with some knowledge of their safety 
and efficacy; some argued that they would never use a substance without being informed. But while 
simultaneous polydrug use was rare, most study participants had used CEDs without a prescription 
as well as more traditional recreational drugs—confirming research that off-label CED users are 
more likely than other drug users to report polydrug use (McCabe & Teter, 2007; cf. Hall et al., 
2005; Schelle et al., 2015). 
 
Conclusion 
Rather than seeing their practices as drug abuse or misuse, our informants perceived and 
experienced CEDs as functional “tools” to achieve specific ends. They experienced both beneficial 
and adverse effects, and pursued strategies to maximize the benefits and minimize the harms. As 
students often expected substances to work as smart drugs, there is a need to provide evidence-
based information on both their possible benefits and harms, as enhancement in one area of 
cognition can be detrimental to another (De Jongh et al., 2008; Smith & Farah, 2011; Husain & 
Mehta, 2011). The adverse effects experienced by individuals diagnosed with ADD/ADHD—some 
of whom reject the diagnosis—increase the likelihood of medications being diverted to their 
undiagnosed peers (cf. Poulin, 2007; Garnier et al., 2010; Vrecko, 2015)—an important 
consideration for policies that aim to reduce harm related to the (off-label) use of prescription drugs. 
 
Finally, the perspectives of CED users deserve a more prominent place when discussing the ethics 
of pharmacological neuroenhancement (e.g. Schelle et al., 2014; Maier et al., 2015b). An open 
discussion between different stakeholders about the risks but also the perceived benefits of using 
pharmaceuticals and other drugs to enhance cognitive performance is vital to ensure that their use, 
when it occurs, happens in an informed and safe way. User participation in this discussion is 
therefore imperative.  
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